Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Virus Diseases 1Liver Diseases 1Hepatitis C, Chronic 1Hepatitis C 1

Interventions

trifluridine tipiracil drug combination 1rubitecan 1repotrectinib 1pevonedistat 1pembrolizumab 1ozanimod 1linifanib 1ledipasvir, sofosbuvir drug combination 1fisogatinib 1ficlatuzumab 1durvalumab 1avelumab 1atezolizumab 1Trabectedin 1Sorafenib 1Ramucirumab 1Irinotecan 1Immunotherapy 1Electroporation 1Dexamethasone 1Bevacizumab 1Azacitidine 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Liver Diseases × ledipasvir, sofosbuvir drug combination × Clear all
NCT02868242 2020-03-02

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Participants Undergoing Cancer Chemotherapy

Gilead Sciences

Phase 2 Completed
19 enrolled 14 charts

Hepatitis C, Liver Diseases, Virus Diseases, Hepatitis C, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡